Literature DB >> 32601124

Prediction of adverse cardiac events in pregnant women with valvular rheumatic heart disease.

Jyoti Baghel1, Anish Keepanasseril2, Ajith Ananthakrishna Pillai3, Nivedita Mondal4, Yavanasuriya Jeganathan1, Pankaj Kundra5.   

Abstract

OBJECTIVE: To assess the incidence of adverse cardiac events in pregnant women with rheumatic valvular heart disease (RHD) and to derive a clinical risk scoring for predicting it.
METHODS: This is an observational study involving pregnant women with RHD, attending a tertiary centre in south India. Data regarding obstetric history, medical history, maternal complications and perinatal outcome till discharge were collected. Eight-hundred and twenty pregnancies among 681 women were included in the analysis. Primary outcome was composite adverse cardiac event defined as occurrence of one or more of complications such as death, cardiac arrest, heart failure, cerebrovascular accident from thromboembolism and new-onset arrhythmias.
RESULTS: Of the 681 women with RHD, 180 (26.3%) were diagnosed during pregnancy. Composite adverse cardiac outcome during pregnancy/post partum occurred in 122 (14.9%) pregnancies, with 12 of them succumbed to the disease. In multivariate analysis, prior adverse cardiac events (OR=8.35, 95% CI 3.54 to 19.71), cardiac medications at booking (OR=0.53, 95% CI 0.32 to 0.86), mitral stenosis (mild OR=2.48, 95% CI 1.08 to 5.69; moderate OR=2.23, 95% CI 1.19 to 4.18; severe OR=7.72,95% 4.05 to 12.89), valve replacement (OR=2.53, 95% CI 1.28 to 5.02) and pulmonary hypertension (OR=6.90, 3.81 to 12.46) were predictive of composite adverse cardiac events with a good discrimination (area under the curve=0.803) and acceptable calibration. A predictive score combining these factors is proposed for clinical utility.
CONCLUSION: Heart failure remains the most common adverse cardiac event during pregnancy or puerperium. Combining the lesion-specific characteristics and clinical information into a predictive score, which is simple and effective, could be used in routine clinical practice. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  pregnancy; valvular heart disease

Mesh:

Year:  2020        PMID: 32601124     DOI: 10.1136/heartjnl-2020-316648

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Effect of Yiqi Buxue Decoction on Hemodynamic Changes of the Uterine Artery and Fetal Umbilical Artery and Pregnancy Outcomes in Pregnant Patients with Pulmonary Arterial Hypertension.

Authors:  Rendong Han; Liya Gao; Hongbo Sun; Mei Li; Chunxia Deng
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-17       Impact factor: 2.629

2.  Maternal and fetal outcomes in pregnant females with rheumatic heart disease.

Authors:  Roopali Khanna; Deepti Chandra; Sangeeta Yadav; Ankit Sahu; Neeta Singh; Sudeep Kumar; Naveen Garg; Satyendra Tewari; Aditya Kapoor; Mandakini Pradhan; Pravin K Goel
Journal:  Indian Heart J       Date:  2021-01-16

3.  Maternal and fetal outcomes of COVID-19 infection in pregnant women with chronic rheumatic heart disease in a South Asian population: A case series.

Authors:  Mamta Rajan; Shikha Sachan; Abhishek Abhinay; Bhupendra Verma
Journal:  J Obstet Gynaecol Res       Date:  2022-03-30       Impact factor: 1.697

4.  Hsa_circ_0003748 promotes disease progression in rheumatic valvular heart disease by sponging miR-577.

Authors:  Xiaoyun Zhang; Yakun Gao; Hongyu Wu; Yong Mao
Journal:  J Clin Lab Anal       Date:  2022-05-09       Impact factor: 3.124

5.  Rheumatic Heart Disease among Pregnant Women with Cardiac Diseases in a Tertiary Care Center of Nepal: A Descriptive Cross-sectional Study.

Authors:  Basant Sharma; Eliza Koirala; Sudhir Regmi; Jaya Dhungana; Bandana Khanal Neupane; Suraj Bhattarai
Journal:  JNMA J Nepal Med Assoc       Date:  2021-05-25       Impact factor: 0.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.